Gotham Asset Management Adds $13M in Charles River Laboratories International, Inc. ($CRL)
Key Points
- Gotham Asset Management changed its Charles River Laboratories International, Inc. ($CRL) stake by 23.8% last quarter, boosting to 358,502 shares worth $67.22 million.
- Wall Street's consensus rating on $CRL is Buy and an average price target of $212.27.
- $CRL last traded around $187.51.
Gotham Asset Management increased its position in Charles River Laboratories International, Inc. ($CRL) by 23.8% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 358,502 shares of Charles River Laboratories International, Inc. after buying 68,986 shares during the quarter. Gotham Asset Management's holdings in Charles River Laboratories International, Inc. were worth $67.22 million as of its most recent filing.
Charles River Laboratories International, Inc. ($CRL) Stock
Charles River Laboratories International, Inc. Earnings
Analysts Set New Price Targets
About Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.